{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:07Z","timestamp":1793725807105,"version":"4.6.1"},"reference-count":82,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,16]]},"DOI":"10.20945\/2359-3997000000563","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:28:48Z","timestamp":1668688128000},"page":"739-747","source":"Crossref","is-referenced-by-count":66,"title":["Male osteoporosis"],"prefix":"10.20945","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-4921","authenticated-orcid":false,"given":"Leonardo","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-581X","authenticated-orcid":false,"given":"Barbara C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"1","key":"key20221117072842_B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11657-018-0540-7","article-title":"Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis","volume":"13","author":"Zamani","year":"2018","unstructured":"Zamani M, Zamani V, Heidari B, Parsian H, Esmaeilnejad-Ganji SM. Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis. Arch Osteoporos. 2018;13(1):129.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"key20221117072842_B2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):609.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"key20221117072842_B3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1186\/s12889-016-3712-7","article-title":"Prevalence of osteoporosis in China: a meta-analysis and systematic review","volume":"16","author":"Chen","year":"2016","unstructured":"Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health. 2016;16(1):1039.","journal-title":"BMC Public Health"},{"issue":"5","key":"key20221117072842_B4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513-21.","journal-title":"JAMA"},{"issue":"1","key":"key20221117072842_B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ecl.2016.11.001","article-title":"Novel Therapies for Postmenopausal Osteoporosis","volume":"46","author":"Bandeira","year":"2017","unstructured":"Bandeira L, Bilezikian JP. Novel Therapies for Postmenopausal Osteoporosis. Endocrinol Metab Clin North Am. 2017;46(1): 207-19.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"key20221117072842_B6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.14740\/jocmr2970w","article-title":"Gender Disparities in Osteoporosis","volume":"9","author":"Alswat","year":"2017","unstructured":"Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res. 2017;9(5):382-7.","journal-title":"J Clin Med Res"},{"issue":"12","key":"key20221117072842_B7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","unstructured":"Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-33.","journal-title":"Osteoporos Int"},{"issue":"10","key":"key20221117072842_B8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00296-014-3035-x","article-title":"Prevalence of morphometric vertebral fractures in old men and the agreement between different methods in the city of Recife, Brazil","volume":"34","author":"Borges","year":"2014","unstructured":"Borges CN, de Almeida JM, Lima D, Cabral M, Bandeira F. Prevalence of morphometric vertebral fractures in old men and the agreement between different methods in the city of Recife, Brazil. Rheumatol Int. 2014;34(10):1387-94.","journal-title":"Rheumatol Int"},{"issue":"2","key":"key20221117072842_B9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1590\/S0482-50042010000200002","article-title":"The burden of osteoporosis in Brazil: regional data from fractures in adult men and women--the Brazilian Osteoporosis Study (BRAZOS)","volume":"50","author":"Pinheiro","year":"2010","unstructured":"Pinheiro MM, Ciconelli RM, Jacques Nde O, Genaro PS, Martini LA, Ferraz MB. The burden of osteoporosis in Brazil: regional data from fractures in adult men and women--the Brazilian Osteoporosis Study (BRAZOS). Rev Bras Reumatol. 2010;50(2):113-27.","journal-title":"Rev Bras Reumatol"},{"key":"key20221117072842_B10","first-page":"241","volume-title":"Protocolos cl\u00ednicos em endocrinologia e diabetes","author":"Borba","year":"2017","unstructured":"Borba V, Costa T. Osteoporose em homens. In: Bandeira F, editor. Protocolos cl\u00ednicos em endocrinologia e diabetes. 2\u00aa ed. Rio de Janeiro: Guanabara Koogan; 2017. p. 241-52.","edition":"2\u00aa ed."},{"issue":"1","key":"key20221117072842_B11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00774-018-0904-5","article-title":"Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures","volume":"37","author":"Jung","year":"2018","unstructured":"Jung Y, Ko Y, Kim HY, Ha YC, Lee YK, Kim TY, et al. Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. J Bone Miner Metab. 2018;37(1):134-41.","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"key20221117072842_B12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1359\/JBMR.050916","article-title":"Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment","volume":"21","author":"Khosla","year":"2006","unstructured":"Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006;21(1):124-31.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221117072842_B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jbmr.171","article-title":"Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study","volume":"26","author":"Macdonald","year":"2011","unstructured":"Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK. Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res. 2011;26(1):50-62.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20221117072842_B14","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1152\/japplphysiol.00564.2003","article-title":"Invited Review: Pathogenesis of osteoporosis","volume":"95","author":"Seeman","year":"2003","unstructured":"Seeman E. Invited Review: Pathogenesis of osteoporosis. J Appl Physiol (1985). 2003;95(5):2142-51.","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"key20221117072842_B15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031211","article-title":"Regulation of Bone Metabolism by Sex Steroids","volume":"8","author":"Khosla","year":"2018","unstructured":"Khosla S, Monroe DG. Regulation of Bone Metabolism by Sex Steroids. Cold Spring Harb Perspect Med. 2018;8(1).","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"key20221117072842_B16","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1210\/jc.2003-030200","article-title":"Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study","volume":"88","author":"Szulc","year":"2003","unstructured":"Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab. 2003;88(11):5240-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20221117072842_B17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12020-013-0083-z","article-title":"Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis","volume":"45","author":"Lassemillante","year":"2014","unstructured":"Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45(3):370-81.","journal-title":"Endocrine"},{"issue":"10","key":"key20221117072842_B18","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1210\/jc.2006-0173","article-title":"Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men","volume":"91","author":"Fink","year":"2006","unstructured":"Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91(10):3908-15.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072842_B19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archinternmed.2007.2","article-title":"Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study","volume":"168","author":"Meier","year":"2008","unstructured":"Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168(1):47-54.","journal-title":"Arch Intern Med"},{"issue":"2","key":"key20221117072842_B20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-64.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20221117072842_B21","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1210\/jc.2009-2635","article-title":"Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study","volume":"95","author":"Cauley","year":"2010","unstructured":"Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE, Bauer DC, et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study. J Clin Endocrinol Metab. 2010;95(9):4314-23.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20221117072842_B22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1359\/jbmr.060110","article-title":"Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden","volume":"21","author":"Mellstr\u00f6m","year":"2006","unstructured":"Mellstr\u00f6m D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21(4):529-35.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20221117072842_B23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tem.2009.09.002","article-title":"Sex steroids and the male skeleton: a tale of two hormones","volume":"21","author":"Callewaert","year":"2010","unstructured":"Callewaert F, Boonen S, Vanderschueren D. Sex steroids and the male skeleton: a tale of two hormones. Trends Endocrinol Metab. 2010;21(2):89-95.","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"key20221117072842_B24","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1359\/jbmr.2000.15.11.2169","article-title":"Mechanical strain stimulates osteoblast proliferation through the estrogen receptor in males as well as females","volume":"15","author":"Damien","year":"2000","unstructured":"Damien E, Price JS, Lanyon LE. Mechanical strain stimulates osteoblast proliferation through the estrogen receptor in males as well as females. J Bone Miner Res. 2000;15(11):2169-77.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"key20221117072842_B25","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1210\/jc.2009-0206","article-title":"The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men","volume":"94","author":"LeBlanc","year":"2009","unstructured":"LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337-46.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117072842_B26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00198-011-1552-y","article-title":"Sex steroids and bone health in older Chinese men","volume":"23","author":"Woo","year":"2012","unstructured":"Woo J, Kwok T, Leung JC, Ohlsson C, Vandenput L, Leung PC. Sex steroids and bone health in older Chinese men. Osteoporos Int. 2012;23(5):1553-62.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20221117072842_B27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11657-020-00755-y","article-title":"DHEA in bone: the role in osteoporosis and fracture healing","volume":"15","author":"Kirby","year":"2020","unstructured":"Kirby DJ, Buchalter DB, Anil U, Leucht P. DHEA in bone: the role in osteoporosis and fracture healing. Arch Osteoporos. 2020;15(1):84.","journal-title":"Arch Osteoporos"},{"issue":"11","key":"key20221117072842_B28","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00198-010-1496-7","article-title":"Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures","volume":"22","author":"D\u2019Amelio","year":"2011","unstructured":"D\u2019Amelio P, Roato I, D\u2019Amico L, Veneziano L, Suman E, Sassi F, et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int. 2011;22(11):2869-77.","journal-title":"Osteoporos Int"},{"issue":"4","key":"key20221117072842_B29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","article-title":"Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications","volume":"22","author":"Lips","year":"2001","unstructured":"Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477-501.","journal-title":"Endocr Rev"},{"issue":"5","key":"key20221117072842_B30","doi-asserted-by":"crossref","first-page":"B267","DOI":"10.1093\/gerona\/52A.5.B267","article-title":"Age-associated loss of power and strength in the upper extremities in women and men","volume":"52","author":"Metter","year":"1997","unstructured":"Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci. 1997;52(5):B267-76.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"key20221117072842_B31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-201x.1999.00590.x","article-title":"Maximal strength and power characteristics in isometric and dynamic actions of the upper and lower extremities in middle-aged and older men","volume":"167","author":"Izquierdo","year":"1999","unstructured":"Izquierdo M, Iba\u00f1ez J, Gorostiaga E, Garrues M, Z\u00fa\u00f1iga A, Ant\u00f3n A, et al. Maximal strength and power characteristics in isometric and dynamic actions of the upper and lower extremities in middle-aged and older men. Acta Physiol Scand. 1999;167(1): 57-68.","journal-title":"Acta Physiol Scand"},{"issue":"2","key":"key20221117072842_B32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ecl.2021.03.001","article-title":"Updates on Osteoporosis in Men","volume":"50","author":"Diab","year":"2021","unstructured":"Diab DL, Watts NB. Updates on Osteoporosis in Men. Endocrinol Metab Clin North Am. 2021;50(2):239-49.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"key20221117072842_B33","first-page":"2792","article-title":"Idiopathic osteoporosis--is the osteoblast to blame?","volume":"82","author":"Khosla","year":"1997","unstructured":"Khosla S. Idiopathic osteoporosis--is the osteoblast to blame? J Clin Endocrinol Metab. 1997;82(9):2792-4.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20221117072842_B34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics","volume":"22","author":"Shuhart","year":"2019","unstructured":"Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019;22(4):453-71.","journal-title":"J Clin Densitom"},{"issue":"11","key":"key20221117072842_B35","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","article-title":"Towards a diagnostic and therapeutic consensus in male osteoporosis","volume":"22","author":"Kanis","year":"2011","unstructured":"Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22(11):2789-98.","journal-title":"Osteoporos Int"},{"issue":"6","key":"key20221117072842_B36","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-22.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117072842_B37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice","volume":"44","author":"Kanis","year":"2009","unstructured":"Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone. 2009;44(5):734-43.","journal-title":"Bone"},{"issue":"5","key":"key20221117072842_B38","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439-43.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20221117072842_B39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ecl.2016.09.005","article-title":"Trabecular Bone Score: A New DXA-Derived Measurement for Fracture Risk Assessment","volume":"46","author":"Silva","year":"2017","unstructured":"Silva BC, Leslie WD. Trabecular Bone Score: A New DXA-Derived Measurement for Fracture Risk Assessment. Endocrinol Metab Clin North Am. 2017;46(1):153-80.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key20221117072842_B40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2013.12.015","article-title":"Vertebral microarchitecture and fragility fracture in men: a TBS study","volume":"62","author":"Leib","year":"2014","unstructured":"Leib E, Winzenrieth R, Aubry-Rozier B, Hans D. Vertebral microarchitecture and fragility fracture in men: a TBS study. Bone. 2014;62:51-5.","journal-title":"Bone"},{"issue":"12","key":"key20221117072842_B41","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1210\/jc.2005-1258","article-title":"In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography","volume":"90","author":"Boutroy","year":"2005","unstructured":"Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508-15.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key20221117072842_B42","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/jgs.12326","article-title":"Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study","volume":"61","author":"Cauley","year":"2013","unstructured":"Cauley JA, Harrison SL, Cawthon PM, Ensrud KE, Danielson ME, Orwoll E, et al. Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study. J Am Geriatr Soc. 2013;61(7):1080-8.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"key20221117072842_B43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","unstructured":"Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221117072842_B44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1359\/jbmr.090826","article-title":"Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men","volume":"25","author":"Cauley","year":"2010","unstructured":"Cauley JA, Parimi N, Ensrud KE, Bauer DC, Cawthon PM, Cummings SR, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res. 2010;25(3):545-53.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20221117072842_B45","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.apmr.2010.08.004","article-title":"Efficacy of a short multidisciplinary falls prevention program for elderly persons with osteoporosis and a fall history: a randomized controlled trial","volume":"91","author":"Smulders","year":"2010","unstructured":"Smulders E, Weerdesteyn V, Groen BE, Duysens J, Eijsbouts A, Laan R, et al. Efficacy of a short multidisciplinary falls prevention program for elderly persons with osteoporosis and a fall history: a randomized controlled trial. Arch Phys Med Rehabil. 2010;91(11):1705-11.","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"key20221117072842_B46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.1532-5415.2006.00912.x","article-title":"Alcohol intake and its relationship with bone mineral density, falls, and fracture risk in older men","volume":"54","author":"Cawthon","year":"2006","unstructured":"Cawthon PM, Harrison SL, Barrett-Connor E, Fink HA, Cauley JA, Lewis CE, et al. Alcohol intake and its relationship with bone mineral density, falls, and fracture risk in older men. J Am Geriatr Soc. 2006;54(11):1649-57.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"key20221117072842_B47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155-62.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20221117072842_B48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197-213.","journal-title":"Ann Intern Med"},{"issue":"9","key":"key20221117072842_B49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-10.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221117072842_B50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","unstructured":"Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29(3):311-5.","journal-title":"Rheumatol Int"},{"issue":"18","key":"key20221117072842_B51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714-23.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221117072842_B52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis","volume":"65","author":"Nayak","year":"2017","unstructured":"Nayak S, Greenspan SL. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2017;65(3):490-5.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"key20221117072842_B53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40744-016-0030-6","article-title":"Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses","volume":"3","author":"Zhou","year":"2016","unstructured":"Zhou J, Wang T, Zhao X, Miller DR, Zhai S. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther. 2016;3(1):117-28.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"key20221117072842_B54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.","journal-title":"J Bone Miner Res"},{"key":"key20221117072842_B55","first-page":"593","article-title":"Osteoporosis in men: epidemiology and treatment with denosumab","volume":"9","author":"Sidlauskas","year":"2014","unstructured":"Sidlauskas KM, Sutton EE, Biddle MA. Osteoporosis in men: epidemiology and treatment with denosumab. Clin Interv Aging. 2014;9:593-601.","journal-title":"Clin Interv Aging"},{"issue":"8","key":"key20221117072842_B56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-55.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221117072842_B57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report","volume":"102","author":"Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report. J Clin Endocrinol Metab. 2017;102(2):354-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221117072842_B58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-8.","journal-title":"J Bone Miner Res"},{"key":"key20221117072842_B59","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020:dgaa756.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221117072842_B60","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration","volume":"110","author":"Tam","year":"1982","unstructured":"Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;110(2):506-12.","journal-title":"Endocrinology"},{"issue":"11","key":"key20221117072842_B61","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O\u2019Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577-83.","journal-title":"Endocrinology"},{"issue":"50","key":"key20221117072842_B62","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism","volume":"278","author":"Bellido","year":"2003","unstructured":"Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278(50):50259-72.","journal-title":"J Biol Chem"},{"issue":"1","key":"key20221117072842_B63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20221117072842_B64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510-6.","journal-title":"Osteoporos Int"},{"issue":"12","key":"key20221117072842_B65","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1\u201334)]","volume":"15","author":"Kurland","year":"2004","unstructured":"Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1\u201334)]. Osteoporos Int. 2004;15(12):992-7.","journal-title":"Osteoporos Int"},{"issue":"11","key":"key20221117072842_B66","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-55.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"key20221117072842_B67","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial","volume":"316","author":"Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016;316(7):722-33.","journal-title":"JAMA"},{"issue":"5","key":"key20221117072842_B68","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.eprac.2022.03.191","article-title":"Abstract #1164092: Efficacy and Safety of Abaloparatide in Men with Osteoporosis. Oral presentation at: American Association of Clinical Endocrinology (AACE); May 12-14, 2022; San Diego, CA","volume":"28","author":"Czerwinski","year":"2022","unstructured":"Czerwinski E, Cardona J, Plebanski R, Chen Y, Pearman L, Li YH, et al. Abstract #1164092: Efficacy and Safety of Abaloparatide in Men with Osteoporosis. Oral presentation at: American Association of Clinical Endocrinology (AACE); May 12-14, 2022; San Diego, CA. Endocrine Practice. 2022;28(5):S78-9.","journal-title":"Endocrine Practice"},{"issue":"9","key":"key20221117072842_B69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3949\/ccjm.88a.21011","article-title":"Teriparatide: Label changes and identifying patients for long-term use","volume":"88","author":"Miller","year":"2021","unstructured":"Miller PD, Lewiecki EM, Krohn K, Schwartz E. Teriparatide: Label changes and identifying patients for long-term use. Cleve Clin J Med. 2021;88(9):489-93.","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"key20221117072842_B70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study","volume":"36","author":"Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res. 2021;36(2):244-51.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20221117072842_B71","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial","volume":"177","author":"Snyder","year":"2017","unstructured":"Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177(4):471-9.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"key20221117072842_B72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/13685538.2013.773420","article-title":"Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study","volume":"16","author":"Bouloux","year":"2013","unstructured":"Bouloux PM, Legros JJ, Elbers JM, Geurts TB, Kaspers MJ, Meehan AG, et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male. 2013;16(2):38-47.","journal-title":"Aging Male"},{"issue":"6","key":"key20221117072842_B73","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1532-5415.2010.02865.x","article-title":"Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty","volume":"58","author":"Kenny","year":"2010","unstructured":"Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134-43.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"key20221117072842_B74","first-page":"1966","article-title":"Effect of testosterone treatment on bone mineral density in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","unstructured":"Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966-72.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117072842_B75","doi-asserted-by":"crossref","first-page":"4602129","DOI":"10.1155\/2017\/4602129","article-title":"Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health","volume":"2017","author":"Golds","year":"2017","unstructured":"Golds G, Houdek D, Arnason T. Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. Int J Endocrinol. 2017;2017:4602129.","journal-title":"Int J Endocrinol"},{"issue":"9","key":"key20221117072842_B76","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis","volume":"103","author":"Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183-93.","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"key20221117072842_B77","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-43.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221117072842_B78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update","volume":"105","author":"Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3):1-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072842_B79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update","volume":"26","author":"Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update. Endocr Pract. 2020;26(1):1-46.","journal-title":"Endocr Pract"},{"issue":"2","key":"key20221117072842_B80","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MJT.0000000000000446","article-title":"Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Xu","year":"2017","unstructured":"Xu Z. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials. Am J Ther. 2017;24(2):e130-8.","journal-title":"Am J Ther"},{"issue":"9","key":"key20221117072842_B81","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20221117072842_B82","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s00198-013-2379-5","article-title":"Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis","volume":"24","author":"Farahmand","year":"2013","unstructured":"Farahmand P, Marin F, Hawkins F, M\u00f6ricke R, Ringe JD, Gl\u00fcer CC, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int. 2013;24(12):2971-81.","journal-title":"Osteoporos Int"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:29:44Z","timestamp":1668688184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/male-osteoporosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,16]]}},"alternative-id":["10.20945\/2359-3997000000563"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000563","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}